Search
Research
National Healthy Skin Guideline; for the Prevention, Treatment and Public Health Control of Impetigo, Scabies, Crusted Scabies and Tinea for Indigenous Populations and Communities in AustraliaAsha Jonathan Marianne Bowen Carapetis AM Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head, Healthy Skin
Research
Novel therapeutics approaches for infants with high-risk infant acute lymphoblastic leukaemiaRishi S. Laurence Sébastien Kotecha Cheung Malinge MB ChB (Hons) MRCPCH FRACP PhD BPharm (Hons) MBA PhD PhD Co-Head, Leukaemia Translational Research
Research
Evaluation of Trauma-Informed Practices in EducationYasmin Harman-Smith BA, BHlthSc(Hons), PhD Head, Early Years Systems Evidence; Head, Tenders Support Unit Yasmin.harman-smith@thekids.org.au Head,
Research
The PneuCaPTIVE studyChristopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Research
Understanding the relative contributions of the lung, respiratory muscles and the blood vessels to severity of chronic lung disease in very preterm infants (PIFCO Follow-up)Graham Ingrid Shannon Hall Laing Simpson BAppSci PhD CRFS FANZSRS FThorSoc FERS BSc PhD BMedSci (hons), PhD Honorary Research Associate Head,
Research
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants (PNEU-PED-EU-1)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Building BridgesGlenn Pearson BA (Education) PhD Candidate Director of First Nations Strategy and Leadership; Head, First Nations Health and Equity Research Director
Research
Penicillin Levels for Rheumatic Heart Disease Study – Remote CohortAsha Jonathan Bowen Carapetis AM BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS Head, Healthy Skin and ARF Prevention Executive
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical